Search research articles
Contact Us
Filters
Showing results (331-340 of 383) with videos related to
Page
of 39
Sort By:
Emerging Infectious Diseases
|
March 11, 2005
Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002
J S Weese, M Archambault, B M Willey, et al.
Journal of the American Society of Hypertension : JASH
|
July 2, 2017
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension
Stefan Engeli, Marcus May, Juerg Nussberger, et al.
Journal of Clinical Microbiology
|
September 17, 1999
Restriction fragment length polymorphisms of virulence plasmids in Rhodococcus equi
S Takai, M Shoda, Y Sasaki, et al.
PLOS Global Public Health
|
June 13, 2025
Who participates in 'participatory design' of WASH infrastructure: A mixed-methods process evaluation
Thea L Mink, Allison P Salinger, Naomi Francis, et al.
Journal of the American College of Cardiology
|
February 21, 2019
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
Michael R Zile, Eileen O'Meara, Brian Claggett, et al.
European Journal of Heart Failure
|
May 13, 2022
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial
Peder L Myhre, Brian L Claggett, Amil M Shah, et al.
Clinical Pharmacology and Therapeutics
|
June 10, 2017
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension
H-L Hsiao, T H Langenickel, J Petruck, et al.
Cardiovascular Therapeutics
|
March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
Zhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
JACC. Heart Failure
|
December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status
Sean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
Clinical Chemistry
|
March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial
Jacob A Udell, David A Morrow, Eugene Braunwald, et al.
Page
of 39
Search research articles
Search
Showing results (331-340 of 383) with videos related to
Sort By:
Page
of 39
Emerging Infectious Diseases
|
March 11, 2005
Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002
J S Weese, M Archambault, B M Willey, et al.
Journal of the American Society of Hypertension : JASH
|
July 2, 2017
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension
Stefan Engeli, Marcus May, Juerg Nussberger, et al.
Journal of Clinical Microbiology
|
September 17, 1999
Restriction fragment length polymorphisms of virulence plasmids in Rhodococcus equi
S Takai, M Shoda, Y Sasaki, et al.
PLOS Global Public Health
|
June 13, 2025
Who participates in 'participatory design' of WASH infrastructure: A mixed-methods process evaluation
Thea L Mink, Allison P Salinger, Naomi Francis, et al.
Journal of the American College of Cardiology
|
February 21, 2019
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
Michael R Zile, Eileen O'Meara, Brian Claggett, et al.
European Journal of Heart Failure
|
May 13, 2022
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial
Peder L Myhre, Brian L Claggett, Amil M Shah, et al.
Clinical Pharmacology and Therapeutics
|
June 10, 2017
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension
H-L Hsiao, T H Langenickel, J Petruck, et al.
Cardiovascular Therapeutics
|
March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
Zhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
JACC. Heart Failure
|
December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status
Sean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
Clinical Chemistry
|
March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial
Jacob A Udell, David A Morrow, Eugene Braunwald, et al.
Page
of 39